Could a new antibody make stem cell transplants a real cure for blood disorders?

This study tests whether adding a new antibody drug (briquilimab, JSP191) to a standard stem cell transplant can help more people with sickle cell disease or beta-thalassemia achieve a full donor blood system, potentially curing their condition. About 40 participants aged 13 and older will receive the transplant and be followed for at least a year. The goal is to see if this approach increases the chance of long-term success without needing lifelong medications.